Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity in Patients with Solid Tumors: a Retrospective, International and Non-interventional Study

NCT04260269 is registered in ClinicalTrials.gov with Helsinki University Central Hospital as lead sponsor.

NCT NCT04260269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04260269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity in Patients with Solid Tumors: a Retrospective, International and Non-interventional Study
Lead sponsor
Helsinki University Central Hospital
Phase
Observational
Overall status
Enrolling by invitation
Start date
June 1, 2018
Completion date
December 31, 2027
Enrollment
200 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor